RxDoctor Payments Data

Julie Willingham

Family · Demorest, GANPI 1568905016

Payments from drug & device makers

$1,083in general payments, 2019–2025

Across 31 payments — averaging $34.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$378
  • Novo Nordisk$257
  • Lilly USA, LLC$159
  • Exact Sciences$58
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$40
  • AstraZeneca$38
  • plus $153 from 7 others

What the payments were for

  • Food & beverage$1,083100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,083 in reported general payments places this provider in the 65th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$47,927
Medicare patients
198
Services billed
833

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide43$66,596
JardianceEmpagliflozin30$29,120
TrulicityDulaglutide25$24,304
FarxigaDapagliflozin Propanediol17$19,679
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$19,260
Tresiba Flextouch U-200Insulin Degludec11$9,994
Lantus SolostarInsulin Glargine,hum.Rec.Anlog36$6,830
VascepaIcosapent Ethyl11$3,834
Fluticasone-SalmeterolFluticasone Propion/Salmeterol20$3,241
Albuterol Sulfate HfaAlbuterol Sulfate64$1,596
Mometasone Furoate13$1,535
Rosuvastatin Calcium111$1,145
Ezetimibe40$1,116
Mirtazapine12$1,078
Gabapentin44$969

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$257$66,59643 claims
Boehringer IngelheimJardiance$20$29,12030 claims
Lilly USA, LLCTrulicity$159$24,30425 claims
AstraZenecaFarxiga$38$19,67917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 6,258 family providers in Georgia.

Other family in Demorest

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →